Hyderabad-based Bharat Biotech International, the manufacturer of Covid-19 vaccine Covaxin, has justified higher pricing of its vaccine when compared to others available for the private sector in India. In a statement issued on Tuesday, the company also said, “the supply price of Covaxin to the government of India at Rs 150 / dose, is a non-competitive price and clearly not sustainable in the long run.” It said that a higher price in private markets is required to offset part of the costs.

It must be noted that a single dose of this made-in-India vaccine can cost around Rs 1,410 (including GST and hospital’s administering charges) at a private facility. On the other hand, Covishield is available at Rs 780 per dose and Russia’s Sputnik V will cost you Rs 1,145 in India.

Hyderabad-based Bharat Biotech International, the manufacturer of Covid-19 vaccine Covaxin, has justified higher pricing of its vaccine when compared to others available for the private sector in India. In a statement issued on Tuesday, the company also said, “the supply price of Covaxin to the government of India at Rs 150 / dose, is a non-competitive price and clearly not sustainable in the long run.” It said that a higher price in private markets is required to offset part of the costs.

It must be noted that a single dose of this made-in-India vaccine can cost around Rs 1,410 (including GST and hospital’s administering charges) at a private facility. On the other hand, Covishield is available at Rs 780 per dose and Russia’s Sputnik V will cost you Rs 1,145 in India.